Top Ten most popular articles on Pharmafile.com this week
pharmafile | July 7, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | most read articles, most read news, top ten
It’s Friday, and we’ve brought together our weekly digest of the articles which proved most popular with our readers. Brexit remains in the headlines, as MPs Hunt and Clark moved from behind cover to suggest that UK will look to work the EU over drug regulation. There was promising research in Alzheimer’s that could lead to new drug targets and AZ sold of two drugs for a tidy profit.
Check out the week’s ten most popular articles on Pharmafile.com now:
Jeremy Hunt, Health Secretary, and Greg Clark, Business Secretary, have made a bold move to suggest that the UK will look to collaborate closely with the EU to navigate drug approvals post-Brexit.
Stada, the German generic drugs manufacturer, saw its two most senior executives leave the company for ‘personal reasons’. Matthias Wiedenfels, CEO, and Helmut Kraft, CFO, left the company only days after a takeover bid by Bain Capital and Cinven had failed to secure enough shareholder support.
A team from the University of Lincoln in the UK has developed a new form of antibiotic, which has proven its ability to defeat existing multidrug-resistant infections.
AstraZeneca’s Daxas (roflumilast) received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD), meaning the therapy could soon be available for routine use on the NHS.
Daiichi Sankyo’s mirogabalin posted trial success in treating patients with post-herpetic neuralgia by hitting its primary endpoint, yet failed to hit its target in a trial focused on fibromyalgia.
GSK is to partner up with Exscientia in a $43 million deal in a bid to utilise the latter’s AI-driven platform to supercharge and streamline its drug discovery business.
Oxford BioMedica announced that it had signed a contract with Novartis to supply the company with materials in a three-year contract.
Gilead is expected to launch injunctive action against rivals Mylan and Actavis over the allegation that they are planning to offer a generic version of Gilead’s antiretroviral HIV drug Truvada.
It is a research breakthrough that has been touted as the biggest development in Alzheimer’s disease research for a quarter of century – scientists have revealed the atomic structure of abnormal tau protein.
The news that AstraZeneca is expected to generate almost $600 million from just two drug sales, Zoming (a migraine therapy) and Seloken (a beta-blocker) proved to be the most interesting to readers.
As the year winds to a close, excitement is rising around the efficacy and availability …
The top ten news stories this week focus on herd immunity, as the Director of …